ADC Therapeutics SA
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M | — |
| Cost of revenue | $5.8M | $5.9M | $2.5M | $3.3M | — |
| Research and development | $104.0M | $109.6M | $127.1M | $186.5M | — |
| Operating income | -$121.5M | -$130.7M | -$166.0M | -$123.3M | — |
| Interest expense | $51.6M | $50.2M | $46.3M | $36.7M | — |
| Pretax income | -$141.6M | -$156.1M | -$195.4M | -$146.8M | — |
| Income tax expense | $1.0M | $166,000 | $39.1M | $227,000 | — |
| Net income | -$142.6M | -$157.8M | -$240.1M | -$157.1M | — |
| Balance Sheet | |||||
| Cash and equivalents | $261.3M | $250.9M | $278.6M | $326.4M | — |
| Current assets | $306.3M | $291.3M | $336.3M | $435.0M | — |
| Total assets | $323.1M | $322.0M | $354.8M | $490.9M | — |
| Current liabilities | $70.2M | $80.5M | $67.7M | $81.9M | — |
| Total liabilities | $509.0M | $524.6M | $503.0M | $411.4M | — |
| Stockholders' equity | -$185.8M | -$202.6M | -$148.2M | $79.5M | $154.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$141.2M | -$123.8M | -$118.7M | -$138.3M | — |
| Depreciation and amortization | $705,000 | $1.3M | $1.2M | $1.1M | — |
| Stock-based compensation | $6.9M | $6.6M | $13.5M | $49.3M | — |
| Capital expenditure | $264,000 | $867,000 | $3.2M | $687,000 | — |
| Free cash flow | -$141.4M | -$124.7M | -$121.9M | -$139.0M | — |
| Impairments | $5.0M | — | — | — | — |
Shares outstanding 127.2M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.